AXLA · Axcella Health Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $56.98M | $43.13M | $37.04M | $25.49M |
| SG&A | $15.81M | $18.71M | $16.80M | $8.41M |
| Total Operating Expenses | $76.99M | $61.85M | $53.84M | $33.90M |
| D&A | $412.0K | $288.0K | $419.0K | $1.07M |
| Operating Income | ($76.99M) | ($61.85M) | ($53.84M) | ($33.90M) |
| Interest Expense | $3.02M | - | - | $2.79M |
| Income Tax | - | - | - | - |
| Net Income | ($81.19M) | ($64.63M) | ($56.53M) | ($59.00M) |
| EPS - Basic | ($1.49) | ($1.78) | - | - |
| EPS - Diluted | ($1.49) | ($1.78) | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash & Equivalents | $17.15M | $23.57M | $92.05M | $92.05M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $4.71M | $4.30M | $2.29M | $2.00M |
| Current Assets | $18.02M | $56.65M | $109.02M | $93.54M |
| Total Assets | $18.93M | $57.73M | $109.59M | $94.36M |
| Current Liabilities | $14.15M | $10.15M | $7.78M | $8.36M |
| Long-term Debt | $0 | $25.07M | $25.22M | $24.90M |
| Total Liabilities | $14.76M | $35.72M | $34.21M | $34.13M |
| Stockholders' Equity | $4.16M | $22.01M | $75.38M | $60.22M |
| Retained Earnings | ($418.43M) | ($337.24M) | ($272.61M) | ($216.09M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Operating Cash Flow | ($69.59M) | ($54.22M) | ($49.77M) | ($30.71M) |
| Investing Cash Flow | $30.92M | $3.05M | ($36.12M) | ($586.0K) |
| Financing Cash Flow | $32.24M | $3.16M | $65.43M | $63.95M |
| CapEx | $426.0K | $275.0K | $239.0K | $659.0K |
| Free Cash Flow | ($70.01M) | ($54.50M) | ($50.01M) | ($31.37M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | 0.86 | 0.84 | 0.88 | 0.53 |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -428.9% | -112.0% | -51.6% | -62.5% |
| Return on equity | -1949.7% | -293.7% | -75.0% | -98.0% |
| Return on invested capital | - | - | - | - |
| Liquidity | ||||
| Current ratio | 1.27 | 5.58 | 14.01 | 11.19 |
| Quick ratio | 1.27 | 5.58 | 14.01 | 11.19 |
| Cash ratio | 1.21 | 2.32 | 11.83 | 11.02 |
| Leverage | ||||
| Debt / Equity | 0.00 | 1.14 | 0.33 | 0.41 |
| Debt / Assets | 0.00 | 0.43 | 0.23 | 0.26 |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | -25.5x | - | - | -12.2x |
| Equity multiplier | 4.55 | 2.62 | 1.45 | 1.57 |
| Liabilities / Assets | 0.78 | 0.62 | 0.31 | 0.36 |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | -24.5% | -14.9% | -58.8% | - |
| Net income growth (YoY) | -25.6% | -14.3% | 4.2% | - |
| EPS growth (YoY) | 16.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | -28.5% | -9.0% | -59.4% | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | -81.1% | -70.8% | 25.2% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Axcella Health Inc. against the 5 most active filers in the same SIC group.